Ben Oshrine

Company: Legend Biotech

Job title: medical director

Seminars:

Panel Discussion: Clinical Advancements in Claudin-Targeted ADCs, Bispecifics, & CAR-T Therapies 11:00 am

Deep diving into the latest advancements and clinical outcomes of ADCs targeting Claudin 18.2 and Claudin 6, with a focus on engineering, payload optimization, and toxicity management specific to claudin targets Examining the role and efficacy of bispecific antibodies in enhancing the immune response against claudin-expressing tumors, supported by insights from preclinical and clinical data…Read more

day: Conference Day 1